CYTO — Cytophage Technologies Income Statement
0.000.00%
Last trade - 00:00- CA$15.42m
- CA$15.63m
Annual income statement for Cytophage Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Operating Interest Expense / Income | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 3.24 | 3.68 | 5.08 | 8.04 |
| Operating Profit | -3.24 | -3.68 | -5.08 | -8.04 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -3.24 | -3.68 | -4.64 | -7.86 |
| Net Income After Taxes | -3.24 | -3.68 | -4.64 | -7.86 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -3.24 | -3.68 | -4.64 | -7.86 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -3.24 | -3.68 | -4.64 | -7.86 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.383 | -0.436 | -0.548 | -0.097 |